Impact of Treatment With VENARUS® on the Level of Monocyte Chemoattractant Protein 1 in Varicose Veins Blood

• Status: Recruiting
• Trial end date: 2021-09-28
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to find if the venoactive drug contained diosmin and hesperidin is able to work against chronic vein-specific inflammation by changing the level of Monocyte Chemoattractant Protein 1. This chemokine is involved in the vein wall remodeling in patients with lower limb varicose veins.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pirogov Russian National Research Medical University

Criteria

Inclusion Criteria:

• • both female and male

• age from 18 to 50 years old

• Verified diagnosis of chronic venous insufficiency CEAP C2-C4

• signed infromed consent

• Absence of any other treatment 2 weeks before the start of the study and throughout the duration of the study

Exclusion Criteria:

• • age less than 18 and more than 50 years

• Previously performed invasive interventions for varicose veins on any of the lower extremities

• No visible varicose veins

• Thrombophlebitis and deep vein thrombosis of the lower extremities in the past

• Taking prohibited pre-trial therapy

• Contraindications to taking Venarus®

• not signed informed consent